Schedule
New Patients Referring Physicians
1-888-663-3488
Find a Doctor
Locations
Careers
Patient Portal
Log In Enroll
English
English Spanish
Donate

Ignacio Garrido-Laguna, MD, PhD, MBA

Ignacio Garrido-Laguna

Ignacio Garrido-Laguna, MD, PhD, MBA

Program Lead, Early Therapeutics Development
Research Department Chair, Early Therapeutics Development
Chair, Department of Early Therapeutics Development

Program: Early Therapeutics Development

  • Overview

    Associations

    • Early Therapeutics Development

  • Participating Trials

    Clinical Trial 24071
    Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
    Condition: Multiple
    Intervention: Cetuximab (); Daraxonrasib (); Erbitux (Cetuximab); RMC-5127 (); RMC-6236 (Daraxonrasib)
    Status: Open

    Clinical Trial 24103
    A First-in-Human Phase 1 Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation
    Condition: Multiple
    Intervention: KST-6051 ()
    Status: Open

    Clinical Trial 24236
    A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
    Condition: Multiple
    Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
    Status: Open

    Clinical Trial 24291
    A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants with Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations
    Condition: Multiple
    Intervention: BLU-924 ()
    Status: Open

    Clinical Trial 24299
    A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
    Condition: Multiple
    Intervention: CGT6297 ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Sang B, Ye LF, Fu Z, Pourfarjam Y, Cuevas-Navarro A, Fan S, Hu F, Washington A, Rodriguez DJ, Vides A, Kar S, Ahler E, Lin KK, Hegde A, Smith JAM, Wolpin BM, Punekar SR, Spira AI, Garrido-Laguna I, Hong DS, Dar AC, Yaeger R, Arbour KC, Lito P. Disrupted molecular glue complex drives RAS inhibitor resistance. Cell. 2026 May.189(10):2918-2933.e17. Pubmedid: 42092352.
    • Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou SHI, Lin T, Kar S, Tao L, Vora R, Hegde A, Aung K, Hong DS. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026 May.394(18):1790-1802. Pubmedid: 42090791.
    • O'Reilly EM, Wainberg ZA, Hendifar AE, Borad MJ, Pietrantonio F, Pant S, Hammel P, Cremolini C, Manji GA, Oberstein PE, Garrido-Laguna I, Springfeld C, Azad NS, Ueno M, Chui SY, Zhang Y, Patel H, Lee Y, Salman Z, Wolpin BM. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026 Jul.395(4):325-337. Pubmedid: 42223072.
    • Le DT, Folprecht G, Varghese AM, Gutierrez M, Noel M, Trikalinos NA, Chen E, Dayyani F, Davis SL, Ma WW, BasuMallick A, Garrido-Laguna I, Osawa M, O'Brien S, Novosiadly RD, Xu K, Greenawalt DM, Dutta S, Twyman Saint Victor C, Lenz HJ. Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer. J Immunother Cancer. 2026 Jan.14(1). Pubmedid: 41571299. Pmcid: PMC12829384.
    • Falchook G, Braganca Xavier C, Van Veenhuyzen D, Malhotra J, Sadeghi S, Kalebasty AR, Wood L, Rahman F, Li E, Pak Y, Khalil M, Spira AI, Sommerhalder D, Garrido-Laguna I, Hong DS. A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors. NPJ Precis Oncol. 2026 Feb.10(1). Pubmedid: 41764244. Pmcid: PMC13065841.
    • Foth M, Kim W, O'Toole K, Murphy B, Justo-Garrido M, Boggaram S, Ghazi P, Brennan E, Wright MI, Shepherd T, Cortes-Sanchez E, Wang Y, Roth JA, Rees MG, Ronan MM, Jiang J, Wasko UN, Jiang A, Becker C, Deacon DC, Holmen SL, VanBrocklin MW, Hu-Lieskovan S, Kinsey CG, Russell JS, Hegde A, Garrido-Laguna I, Holderfield M, Singh M, McMahon M. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multiselective Inhibitors in NRAS-Mutated Melanoma. Cancer Res. 2026 Aug.86(16):4136-4155. Pubmedid: 42171647. Pmcid: PMC13335394.
    • Aronchik I, Kar S, Zhuang Y, Ahler E, Lai LP, Seshadri V, Yang YC, Bulle A, Menard M, Nayak B, Labrecque MP, Dilly J, Kim E, Jiang L, Yano J, Wasko UN, Helland C, Bredeson S, Garrick B, Gindin Y, Sickler B, Wei X, Seamon K, Jiang J, Lim KH, Holderfield M, Quintana E, Hegde A, Salman Z, Starodub A, Spira A, Park W, Hong DS, Barve M, Pelster M, Sommerhalder D, Punekar SR, Garrido-Laguna I, Wolpin BM, Maitra A, Gustafson WC, Kelsey S, Smith JAM, Lin KK, Aguirre AJ, Singh M. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer. Nat Med. 2026 Aug.32(8):2865-2877. Pubmedid: 42581230. Pmcid: PMC13472880.
    • Miotke L, Norton C, Rubnitz Z, Florou V, Nevala-Plagemann C, Garrido-Laguna I. Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer. ESMO Open. 2025 Sep.10(9):105768. Pubmedid: 40930024. Pmcid: PMC12455129.
    • Gouda MA, Ballesteros PA, Garrido-Laguna I, Rodon J. Efficacy assessment in phase I clinical trials: endpoints and challenges. Ann Oncol. 2025 May.36(5):507-519. Pubmedid: 40049448.
    • Norton C, Shaw MS, Rubnitz Z, Smith J, Soares HP, Nevala-Plagemann CD, Garrido-Laguna I, Florou V. KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma. JAMA Netw Open. 2025 Jan.8(1):e2453588. Pubmedid: 39777438. Pmcid: PMC11707629.
    • Rubnitz Z, Nevala-Plagemann C, Florou V, Garrido-Laguna I. Gemcitabine-induced myositis in a patient with pancreatic cancer. BMJ Case Rep. 2025 Jan.18(1). Pubmedid: 39842889. Pmcid: PMC11759102.
    • Foth M, Kim W, O'Toole KT, Murphy B, Justo-Garrido M, Boggaram SS, Ghazi PC, Brennan E, Wright MI, Shepherd T, Sanchez EC, Wang Y, Roth JA, Rees MG, Ronan MM, Jiang J, Wasko U, Jiang A, Becker C, Deacon D, Hu-Lieskovan S, Kinsey CG, Russel J, Hegde A, Garrido-Laguna I, Holderfield M, Singh M, McMahon M. Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma. bioRxiv. 2025 Dec. Pubmedid: 41446219. Pmcid: PMC12724509.
    • Tran B, Voskoboynik M, Bendell J, Gutierrez M, Lemech C, Day D, Frentzas S, Garrido-Laguna I, Standifer N, Wang F, Ferte C, Wang Y, Das M, Carneiro BA. A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy. 2024 Sep.16(11):759-774. Pubmedid: 39264730. Pmcid: PMC11421296.
    • Faber EB, Krause HB, Amin K, Walker P, Hosein PJ, Shields AF, Lenz HJ, Prakash A, Goel S, Oberley M, Malleo G, Luchini C, Hwang J, Florou V, Garrido-Laguna I, Lou E. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets. JCO Precis Oncol. 2024 May.8:e2300595. Pubmedid: 38723231. Pmcid: PMC11161235.
    • Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, Garrido-Laguna I, Peterson PM, Borazanci E, Johnson M, Ceccarelli M, Pelzer U. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers (Basel). 2024 Mar.16(7). Pubmedid: 38611000. Pmcid: PMC11010910.
    • Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Lee J, Affolter K, Mulvihill SJ, Beg MS, Wang-Gillam A, Wade JL, Guthrie KA, Chiorean EG, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty GL. Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2024 Jun.166(6):1114-1129. Pubmedid: 38244727. Pmcid: PMC11102852.
    • Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2024 Jun.22(2 D). Pubmedid: 38862008.
    • Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson S. Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (C. EClinicalMedicine. 2024 Jan.67:102376. Pubmedid: 38204489. Pmcid: PMC10776423.
    • Nevala-Plagemann C, Conroy T, Garrido-Laguna I. Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3'. Nat Rev Clin Oncol. 2024 Dec.21(12):902. Pubmedid: 39455871.
    • Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Jones F, Gurski L. NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Ne. 2024 Aug.22(6):366-375. Pubmedid: 39151454.
    • Nevala-Plagemann C, Garrido-Laguna I. NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?. Nat Rev Clin Oncol. 2024 Aug.21(8):567-568. Pubmedid: 38664532.
    • Beatty GL, Delman D, Yu J, Liu M, Li JH, Zhang L, Lee JW, Chang RB, Bahary N, Kennedy EP, Wang-Gillam A, Rossi GR, Garrido-Laguna I. Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration. Clin Cancer Res. 2023 Sep.29(17):3514-3525. Pubmedid: 37534996. Pmcid: PMC10530235.
    • Florou V, Elliott A, Bailey MH, Stone D, Affolter K, Soares HP, Nevala-Plagemann C, Scaife C, Walker P, Korn WM, Lou E, Shroff RT, Hosein PJ, Garrido-Laguna I. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC. Clin Cancer Res. 2023 Sep.29(17):3408-3417. Pubmedid: 37266563.
    • Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler ME, Hütter-Krönke ML, Perotti A, Juif PE, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer. 2023 Nov.11(11). Pubmedid: 38030303. Pmcid: PMC10689375.
    • Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, Kamal S, Marzullo L, De Marco M, Falco A, Genovese A, Adler JM, De Laurenzi V, Adler DG, Affolter KE, Garrido-Laguna I, Scaife CL, Turco MC, Mulvihill SJ. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO Clin Cancer Inform. 2023 Mar.7:e2200160. Pubmedid: 36913644. Pmcid: PMC10530881.
    • Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2023 Jun.21(6):653-677. Pubmedid: 37308125.
    • Parsons M, Lloyd S, Johnson S, Scaife C, Soares H, Kim R, Kim R, Garrido-Laguna I, Tao R. The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. J Gastrointest Cancer. 2023 Jun.54(2):492-500. Pubmedid: 35445343. Pmcid: PMC9020757.
    • Moraitis AM, Rose NB, Johnson AF, Dunston ER, Garrido-Laguna I, Hobson P, Barber K, Basen-Engquist K, Coletta AM. Feasibility and acceptability of an mHealth, home-based exercise intervention in colorectal cancer survivors: A pilot randomized controlled trial. PLoS One. 2023 Jun.18(6):e0287152. Pubmedid: 37347792. Pmcid: PMC10286977.
    • Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q, Hong DS. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023 Jan.388(1):33-43. Pubmedid: 36546651. Pmcid: PMC10506456.
    • Nevala-Plagemann C, Sama S, Ying J, Shen J, Haaland B, Florou V, Garrido-Laguna I. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Ne. 2023 Feb.21(3):257-264. Pubmedid: 36812939.
    • Smith JT, Sama S, Florou V, Nevala-Plagemann C, Garrido-Laguna I. Durable response to first-line PARP inhibition in BRCA-mutated metastatic cholangiocarcinoma: case report. J Gastrointest Oncol. 2023 Dec.14(6):2637-2643. Pubmedid: 38196540. Pmcid: PMC10772693.
    • El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, Noto P, Tarkar A, Garrido-Laguna I, Calvo E, Rodón J, Tran B, O'Dwyer PJ, Cuker A, Abdul Razak AR. Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors. Brit J Cancer. 2023 Aug.129(2):309-317. Pubmedid: 37237172. Pmcid: PMC10338470.
    • Rodon Ahnert J, Tan DS, Garrido-Laguna I, Harb W, Bessudo A, Beck JT, Rottey S, Bahary N, Kotecki N, Zhu Z, Deng S, Kowalski K, Wei C, Pathan N, Laliberte RJ, Messersmith WA. Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial. ESMO Open. 2023 Aug.8(4):101584. Pubmedid: 37379764. Pmcid: PMC10515283.
    • Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer. 2023 Aug.11(8). Pubmedid: 37586768. Pmcid: PMC10432623.
    • Florou V, Garrido-Laguna I. Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer. Curr Oncol Rep. 2022 Sep.24(9):1107-1112. Pubmedid: 35412226.
    • Miotke L, Nevala-Plagemann C, Ying J, Florou V, Haaland B, Garrido-Laguna I. Treatment outcomes in recurrent versus de novo metastatic pancreatic adenocarcinoma: a real world study. BMC Cancer. 2022 Oct.22(1):1054. Pubmedid: 36224524. Pmcid: PMC9554966.
    • Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2022 Oct.20(10):1139-1167. Pubmedid: 36240850.
    • Hidalgo M, Garcia-Carbonero R, Lim KH, Messersmith WA, Garrido-Laguna I, Borazanci E, Lowy AM, Medina Rodriguez L, Laheru D, Salvador-Barbero B, Malumbres M, Shields DJ, Grossman JE, Huang X, Tammaro M, Martini JF, Yu Y, Kern K, Macarulla T. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas. Cancer Res Commun. 2022 Nov.2(11):1326-1333. Pubmedid: 36970055. Pmcid: PMC10035387.
    • Powderly JD, Klempner SJ, Naing A, Bendell J, Garrido-Laguna I, Catenacci DVT, Taylor MH, Lee JJ, Zheng F, Zhou F, Gong X, Gowda H, Beatty GL. Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study. Oncologist. 2022 Nov.27(11):905-e848. Pubmedid: 36156099. Pmcid: PMC9632315.
    • Naing A, Powderly JD, Nemunaitis JJ, Luke JJ, Mansfield AS, Messersmith WA, Sahebjam S, LoRusso PM, Garrido-Laguna I, Leopold L, Geschwindt R, Ding K, Smith M, Berlin JD. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 Mar.10(3). Pubmedid: 35288468. Pmcid: PMC8921936.
    • Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Mar.28(5):882-892. Pubmedid: 34844977.
    • Nevala-Plagemann C, Iyengar S, Trunk AD, Pappas L, Haaland B, Garrido-Laguna I. Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States. J Natl Compr Canc Ne. 2022 Feb.20(3):268-275. Pubmedid: 35120306.
    • Trunk A, Braithwaite M, Nevala-Plagemann C, Pappas L, Haaland B, Garrido-Laguna I. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. J Natl Compr Canc Ne. 2022 Feb.20(2):144-150. Pubmedid: 35130499.
    • Pauley K, Koptiuch C, Greenberg S, Kohlmann W, Jeter J, Colonna S, Werner T, Kinsey C, Gilcrease G, Weis J, Whisenant J, Florou V, Garrido-Laguna I. Discrepancies between tumor genomic profiling and germline genetic testing. ESMO Open. 2022 Aug.7(4):100526. Pubmedid: 35780590. Pmcid: PMC9511791.
    • Harding JJ, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, Hooper AT, Kamperschroer C, Max SI, Moreau A, Shannon M, Wong GY, Hong DS. A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Front Immunol. 2022 Apr.13:845417. Pubmedid: 35493516. Pmcid: PMC9047766.
    • Iyengar S, Nevala-Plagemann C, Garrido-Laguna I. Updates on adjuvant and neoadjuvant treatment strategies for surgically resectable and borderline resectable pancreatic ductal adenocarcinoma. Ther Adv Med Oncol. 2021 Sep.13. Pubmedid: 34552668. Pmcid: PMC8450613.
    • Affolter KE, Hellwig S, Nix DA, Bronner MP, Thomas A, Fuertes CL, Hamil CL, Garrido-Laguna I, Scaife CL, Mulvihill SJ, Underhill HR. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma. Neoplasia. 2021 Sep.23(9):859-869. Pubmedid: 34298235. Pmcid: PMC8322473.
    • Foth M, Garrido-Laguna I, Kinsey CG. Therapeutic Targeting of Autophagy in Pancreatic Cancer. Surg Oncol Clin N Am. 2021 Oct.30(4):709-718. Pubmedid: 34511191.
    • Gan HK, Millward M, Jalving M, Garrido-Laguna I, Lickliter JD, Schellens JHM, Lolkema MP, Van Herpen CLM, Hug B, Tang L, O'Connor-Semmes R, Gagnon R, Ellis C, Ganji G, Matheny C, Drilon A. A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors. Oncologist. 2021 Oct.26(10):e1844-e1853. Pubmedid: 34132450. Pmcid: PMC8488777.
    • Florou V, Nevala-Plagemann C, Whisenant J, Maeda P, Gilcrease GW, Garrido-Laguna I. Clinical Activity of Selitrectinib in a Patient With Mammary Analogue Secretory Carcinoma of the Parotid Gland With Secondary Resistance to Entrectinib. J Natl Compr Canc Ne. 2021 May.19(5):478-482. Pubmedid: 34030125.
    • Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Mar.19(3):329-359. Pubmedid: 33724754.
    • Kalasekar SM, Garrido-Laguna I, Evason KJ. Immune Checkpoint Inhibitors in Combinations for Hepatocellular Carcinoma. Hepatology. 2021 Jun.73(6):2591-2593. Pubmedid: 33434363.
    • Florou V, Puri S, Garrido-Laguna I, Wilky BA. Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. Ann Transl Med. 2021 Jun.9(12):1035. Pubmedid: 34277835. Pmcid: PMC8267318.
    • Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I. Emerging Treatment Strategies in Pancreatic Cancer. Pancreas. 2021 Jul.50(6):773-787. Pubmedid: 34398070.
    • Baron MK, Wang X, Nevala-Plagemann C, Moser JC, Haaland B, Garrido-Laguna I. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma. Pancreas. 2021 Jul.50(6):796-802. Pubmedid: 34347727.
    • Parsons M, Lloyd S, Johnson S, Scaife C, Varghese T, Glasgow R, Garrido-Laguna I, Tao R. Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Ann Surg Oncol. 2021 Feb.28(2):663-675. Pubmedid: 32648178.
    • Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clin Cancer Res. 2021 Dec.27(23):6314-6322. Pubmedid: 34580114. Pmcid: PMC8639715.
    • Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D. Metastatic Pancreatic Cancer: ASCO Guideline Update. J Clin Oncol. 2020 Sep.38(27):3217-3230. Pubmedid: 32755482. Pmcid: PMC12974607.
    • Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 Nov.26(21):5579-5587. Pubmedid: 33055173.
    • Gruhl JD, Garrido-Laguna I, Francis SR, Affolter K, Tao R, Lloyd S. The impact of squamous cell carcinoma histology on outcomes in nonmetastatic pancreatic cancer. Cancer Med. 2020 Mar.9(5):1703-1711. Pubmedid: 31945808. Pmcid: PMC7050091.
    • Florou V, Nevala-Plagemann C, Barber KE, Mastroianni JN, Cavalieri CC, Garrido-Laguna I. Treatment Rechallenge With Checkpoint Inhibition in Patients With Mismatch Repair-Deficient Pancreatic Cancer After Planned Treatment Interruption. JCO Precis Oncol. 2020 Jun.4. Pubmedid: 33542969. Pmcid: PMC7846057.
    • Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Ne. 2020 Jul.18(7):806-815. Pubmedid: 32634771.
    • Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb.21(2):271-282. Pubmedid: 31838007. Pmcid: PMC7461630.
    • Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol. 2020 Feb.17(2):108-123. Pubmedid: 31705130.
    • Nix DA, Hellwig S, Conley C, Thomas A, Fuertes CL, Hamil CL, Bhetariya PJ, Garrido-Laguna I, Marth GT, Bronner MP, Underhill HR. The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA. PLoS One. 2020 Feb.15(2):e0229063. Pubmedid: 32084206. Pmcid: PMC7034809.
    • Vaishnavi A, Scherzer MT, Kinsey CG, Parkman GL, Truong A, Ghazi P, Schuman S, Battistone B, Garrido-Laguna I, McMahon M. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer. Cell Rep. 2020 Aug.32(5):107994. Pubmedid: 32755586. Pmcid: PMC7478141.
    • Florou V, Garrido-Laguna I. Immune Checkpoint Inhibitors in Gastrointestinal Malignancies: What Is the Path Forward?. J Immunother Precis Oncol. 2020 Aug.3(3):137-139. Pubmedid: 35663253. Pmcid: PMC9165577.
    • Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2019 Sep.17(9):1109-1133. Pubmedid: 31487687. Pmcid: PMC10191182.
    • Garrido-Laguna I, Krop I, Burris HA, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R, Hong DS. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 Oct.145(7):1798-1808. Pubmedid: 30680712. Pmcid: PMC6875752.
    • Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S. Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs. 2019 Jun.37(3):482-489. Pubmedid: 30302599.
    • Nevala-Plagemann C, Moser J, Gilcrease GW, Garrido-Laguna I. Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab. ESMO Open. 2019 Jul.4(4):e000539. Pubmedid: 31423338. Pmcid: PMC6677976.
    • Swords DS, Francis SR, Lloyd S, Garrido-Laguna I, Mulvihill SJ, Gruhl JD, Christensen MC, Stoddard GJ, Firpo MA, Scaife CL. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy. J Gastrointest Surg. 2019 Jul.23(7):1401-1413. Pubmedid: 30187332.
    • Liang WS, Vergilio JA, Salhia B, Huang HJ, Oki Y, Garrido-Laguna I, Park H, Westin JR, Meric-Bernstam F, Fabrizio D, Miller VA, Stephens PJ, Fanale MA, Ross JS, Janku F. Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist. 2019 Feb.24(2):219-228. Pubmedid: 30108156. Pmcid: PMC6369943.
    • Lloyd S, Baraghoshi D, Tao R, Garrido-Laguna I, Gilcrease GW, Whisenant J, Weis JR, Scaife C, Pickron TB, Huang LC, Monroe MM, Abdelaziz S, Fraser AM, Smith KR, Deshmukh V, Newman M, Rowe KG, Snyder J, Samadder NJ, Hashibe M. Mental Health Disorders are More Common in Colorectal Cancer Survivors and Associated With Decreased Overall Survival. Am J Clin Oncol. 2019 Apr.42(4):355-362. Pubmedid: 30844850. Pmcid: PMC6433523.
    • Solomon BL, Garrido-Laguna I. TIGIT: a novel immunotherapy target moving from bench to bedside. Cancer Immunol Immun. 2018 Nov.67(11):1659-1667. Pubmedid: 30232519. Pmcid: PMC11028339.
    • Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C. Entrectinib in TRK and ROS1 Fusion-Positive Metastatic Pancreatic Cancer. JCO Precis Oncol. 2018 Nov.2:1-7. Pubmedid: 35135135.
    • Torgeson A, Garrido-Laguna I, Tao R, Cannon GM, Scaife CL, Lloyd S. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. ESMO Open. 2018 Jan.3(1):e000282. Pubmedid: 29387477. Pmcid: PMC5786921.
    • Torgeson A, Tao R, Garrido-Laguna I, Willen B, Dursteler A, Lloyd S. Large database utilization in health outcomes research in pancreatic cancer: an update. J Gastrointest Oncol. 2018 Dec.9(6):996-1004. Pubmedid: 30603118. Pmcid: PMC6286942.
    • Gajiwala S, Torgeson A, Garrido-Laguna I, Kinsey C, Lloyd S. Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. J Gastrointest Oncol. 2018 Dec.9(6):1014-1026. Pubmedid: 30603120. Pmcid: PMC6286952.
    • Sohal DPS, Kennedy EB, Khorana A, Copur MS, Crane CH, Garrido-Laguna I, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Ramanathan RK, Ruggiero JT, Shah MA, Urba S, Uronis HE, Lau MW, Laheru D. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 Aug.36(24):2545-2556. Pubmedid: 29791286. Pmcid: PMC7504972.
    • Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Engstrom PF, Garrido-Laguna I, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wuthrick E, Gregory KM, Freedman-Cass DA. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Ne. 2018 Apr.16(4):359-369. Pubmedid: 29632055. Pmcid: PMC10184502.
    • Solomon BL, Garrido-Laguna I. Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncol. 2018 Apr.14(10):947-962. Pubmedid: 29542354. Pmcid: PMC5925434.
    • Nevala-Plagemann C, Francis S, Cavalieri C, Tao R, Whisenant J, Glasgow R, Scaife C, Lloyd S, Garrido-Laguna I. Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open. 2018.3(5):e000386. Pubmedid: 30094072. Pmcid: PMC6069924.
    • Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I. Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy. 2017 Sep.9(10):797-804. Pubmedid: 28877632.
    • Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep.17(1):646. Pubmedid: 28899363. Pmcid: PMC5596462.
    • Torgeson A, Lloyd S, Boothe D, Tao R, Whisenant J, Garrido-Laguna I, Cannon GM. Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. Cancer. 2017 Oct.123(19):3816-3824. Pubmedid: 28621885.
    • Rengifo-Cam W, Jasperson K, Garrido-Laguna I, Colman H, Scaife C, Samowitz W, Samadder NJ. A 30-Year-Old Man with Three Primary Malignancies: A Case of Constitutional Mismatch Repair Deficiency. ACG Case Rep J. 2017 Mar.4:e34. Pubmedid: 28286799. Pmcid: PMC5340720.
    • Au TH, Wang K, Stenehjem D, Garrido-Laguna I. Personalized and precision medicine: integrating genomics into treatment decisions in gastrointestinal malignancies. J Gastrointest Oncol. 2017 Jun.8(3):387-404. Pubmedid: 28736627. Pmcid: PMC5506274.
    • Torgeson A, Lloyd S, Boothe D, Cannon G, Garrido-Laguna I, Whisenant J, Lewis M, Kim R, Scaife C, Tao R. Chemoradiation Therapy for Unresected Extrahepatic Cholangiocarcinoma: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2017 Dec.24(13):4001-4008. Pubmedid: 29043526.
    • Wynn D, Merriman J, Patel AB, Hitchcock YJ, Garrido-Laguna I, Renner D, Clardy SL. Paraneoplastic opsoclonus associated with squamous cell carcinoma of the tongue. Clin Neurol Neurosurg. 2016 Oct.149:11-14. Pubmedid: 27450762.
    • Park H, Garrido-Laguna I, Naing A, Fu S, Falchook GS, Piha-Paul SA, Wheler JJ, Hong DS, Tsimberidou AM, Subbiah V, Zinner RG, Kaseb AO, Patel S, Fanale MA, Velez-Bravo VM, Meric-Bernstam F, Kurzrock R, Janku F. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct.7(41):67521-67531. Pubmedid: 27589687. Pmcid: PMC5341894.
    • Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. Mol Cancer Ther. 2016 Apr.15(4):533-547. Pubmedid: 27009213.
    • Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience. 2015 Mar.2(3):285-293. Pubmedid: 25897431. Pmcid: PMC4394134.
    • Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015 Jun.12(6):319-334. Pubmedid: 25824606.
    • Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. Discov Med. 2015 Feb.19(103):109-116. Pubmedid: 25725225.
    • Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. Discov Med. 2015 Feb.19(103):101-108. Pubmedid: 25725224.
    • Patel SB, Gill D, Garrido-Laguna I. Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther. 2015 Dec.9:75-86. Pubmedid: 26770060. Pmcid: PMC4706127.
    • Vidwans SJ, Turski ML, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Subbiah V, Rodon J, Kurzrock R. A framework for genomic biomarker actionability and its use in clinical decision making. Oncoscience. 2014 Oct.1(10):614-623. Pubmedid: 25593991. Pmcid: PMC4278279.
    • Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul.120(14):2164-2173. Pubmedid: 24752867.
    • Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. Discov Med. 2014 Dec.18(101):331-339. Pubmedid: 25549704.
    • Samadder NJ, Curtin K, Wong J, Tuohy TM, Mineau GP, Smith KR, Pimentel R, Pappas L, Boucher K, Garrido-Laguna I, Provenzale D, Burt RW. Epidemiology and familial risk of synchronous and metachronous colorectal cancer: a population-based study in Utah. Clin Gastroenterol H. 2014 Dec.12(12):2078-84.e1. Pubmedid: 24768809.
    • Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V. Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. Discov Med. 2014 Dec.18(101):323-330. Pubmedid: 25549703.
    • Reese Z, Patel S, Stenehjem DD, Garrido-Laguna I. Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX. J Gastrointest Cancer. 2014 Dec.45 Suppl 1:278-281. Pubmedid: 25367745.
    • Garrido-Laguna I, McGregor KA, Wade M, Weis J, Gilcrease W, Burr L, Soldi R, Jakubowski L, Davidson C, Morrell G, Olpin JD, Boucher K, Jones D, Sharma S. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs. 2013 Oct.31(5):1257-1264. Pubmedid: 23504398.
    • Garrido-Laguna I, Hong DS, Janku F, Nguyen LM, Falchook GS, Fu S, Wheler JJ, Luthra R, Naing A, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012 Sep.7(5):e38033. Pubmedid: 22675430. Pmcid: PMC3364990.
    • Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar.30(8):777-782. Pubmedid: 22271473. Pmcid: PMC3295566.
    • Garrido-Laguna I, Janku F. Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?. J Clin Oncol. 2012 Mar.30(8):892-893. Pubmedid: 22291080.
    • Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar.118(5):1422-1428. Pubmedid: 21823111.
    • Hong DS, Patel JC, Wheler J, Naing A, Garrido-Laguna I, Falchook G, Fu S, Tsimberidou AM, Kopetz S, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec.11(4):297-303. Pubmedid: 22537607.
    • Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec.3(12):1566-1575. Pubmedid: 23248156. Pmcid: PMC3681495.
    • Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011 Sep.17(17):5793-5800. Pubmedid: 21742805. Pmcid: PMC3210576.
    • Janku F, Garrido-Laguna I, Petruzelka LB, Stewart DJ, Kurzrock R. Novel therapeutic targets in non-small cell lung cancer. J Thorac Oncol. 2011 Sep.6(9):1601-1612. Pubmedid: 21849857.
    • Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther. 2011 Oct.12(7):598-609. Pubmedid: 21768779. Pmcid: PMC3218385.
    • Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar.10(3):558-565. Pubmedid: 21216929. Pmcid: PMC3072168.
    • Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011 Jan.10(1):3-8. Pubmedid: 21135251. Pmcid: PMC3307340.
    • Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011 Dec.6(7):e22769. Pubmedid: 21829508. Pmcid: PMC3146490.
    • Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, Strawn S, Wick MJ, Martell J, Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther. 2011 Aug.10(8):1311-1316. Pubmedid: 21673092. Pmcid: PMC4629061.
    • Garrido-Laguna I, Hidalgo M, Kurzrock R. The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol. 2011 Aug.8(9):562-566. Pubmedid: 21808269.
    • Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011 Aug.16(3):327-335. Pubmedid: 21339262. Pmcid: PMC3228100.
    • Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Response of histiocytoses to imatinib mesylate: fire to ashes. J Clin Oncol. 2010 Nov.28(31):e633-e636. Pubmedid: 20733125.
    • Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment. Clin Cancer Res. 2010 Aug.16(15):4031-4037. Pubmedid: 20525754.
    • Garrido-Laguna I, Tan AC, Uson M, Angenendt M, Ma WW, Villaroel MC, Zhao M, Rajeshkumar NV, Jimeno A, Donehower R, Iacobuzio-Donahue C, Barrett M, Rudek MA, Rubio-Viqueira B, Laheru D, Hidalgo M. Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. Brit J Cancer. 2010 Aug.103(5):649-655. Pubmedid: 20664591. Pmcid: PMC2938261.
    • Garrido-Laguna I, Amador ML, Ruiz J, Cortés-Funes H. Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer. Clin Transl Oncol. 2009 Mar.11(3):183-185. Pubmedid: 19293057.
    • Martín-Santamaría S, Rodríguez JJ, de Pascual-Teresa S, Gordon S, Bengtsson M, Garrido-Laguna I, Rubio-Viqueira B, López-Casas PP, Hidalgo M, de Pascual-Teresa B, Ramos A. New scaffolds for the design of selective estrogen receptor modulators. Org Biomol Chem. 2008 Oct.6(19):3486-3496. Pubmedid: 19082149.
    • Garrido-Laguna I, Ponz M, Espinós J. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma?. J Clin Oncol. 2007 Mar.25(9):1149. Pubmedid: 17369585.
    • Garrido-Laguna I, Fernandez Hidalgo O, Garcia Foncillas J. MRI evaluation of breast cancer. N Engl J Med. 2007 Jul.357(2):191. Pubmedid: 17625133.

Find a Researcher Search

Cambiar el idioma

Si no encuentra la información que busca o si desea programar una cita, llámenos gratis al 1-888-663-3488.

Gracias.

 

 

 

 

Cancel | Cancelar OK